Efectividad de los parches de lidocaína em el tratamento de la neuralgia posherética em la cara: revisión sistemática y metanálises
DOI:
https://doi.org/10.33448/rsd-v10i13.21513Palabras clave:
Anestésicos; Lidocaína; Infección de herpes; Neuralgia.Resumen
La neuralgia posherpética es una de las neuropatías más desafiantes. Hay muchas opciones de tratamiento con distintos grados de eficacia. El presente trabajo realizó una revisión sistemática sobre el uso de parches de lidocaína en el tratamiento de esta neuralgia. Se realizó una revisión sistemática siguiendo el protocolo PRISMA sobre parches de lidocaína en el tratamiento de la neuralgia postherpética. El protocolo fue registrado en el sistema PROSPERO. El metanálisis se creó con el software RevMan. Se incluyeron nueve artículos según los criterios de inclusión y exclusión. Se elaboró una tabla de los artículos incluidos y el motivo de la exclusión. Los parches de lidocaína son efectivos en el tratamiento de la neuralgia postherpética y son más seguros que otros medicamentos, lo que los hace útiles en pacientes ancianos con comorbilidades, donde el uso de otros medicamentos genera una serie de efectos adversos. Los parches de lidocaína deben considerarse como la terapia de primera elección en el tratamiento de la neuralgia facial postherpética debido a su seguridad y rentabilidad.
Citas
Baron, R., Mayoral, V., Leijon, G., Binder, A., Steigerwald, I., & Serpell, M. (2009) 5% Lidocaine medicated plaster versus pregabalin in post-herpetic neuralgia and diabetic polyneuropathy: An open-label, non-inferiority two-stage RCT study. Curr Med Res Opin. 25(7):1663–76.
Baron, R., Mayoral, V., Leijon, G., Binder, A., Steigerwald, I., & Serpell, M. (2009) Efficacy and safety of 5% lidocaine (lignocaine) medicated plaster in comparison with pregabalin in patients with postherpetic neuralgia and diabetic polyneuropathy: Interim analysis from an open-label, two-stage adaptive, randomized, controlled trial. Clin Drug Investig. 29(4):231–41.
Baron, R., Mayoral, V., Leijon, G., Binder, A., Steigerwald, I., & Serpell, M. (2009) Efficacy and safety of combination therapy with 5% lidocaine medicated plaster and pregabalin in post-herpetic neuralgia and diabetic polyneuropathy. Curr Med Res Opin. 25(7):1677–87.
Binder, A., Bruxelle, J., Rogers, P., Hans, G., Bösl, I., & Baron, R. (2009) Topical 5% lidocaine (lignocaine) medicated plaster treatment for post-herpetic neuralgia: Results of a double-blind, placebo-controlled, multinational efficacy and safety trial. Clin Drug Investig. 29(6):393–408.
Binder, A., Rogers, P., Hans, G., & Baron, R. (2016) Impact of topical 5% lidocaine-medicated plasters on sleep and quality of life in patients with postherpetic neuralgia. Pain Manag. 6(3):229–39.
Bruckenthal, P., & Barkin, R. L. (2013) Options for treating postherpetic neuralgia in the medically complicated patient. Vol. 9, Therapeutics and Clinical Risk Management. 329–40.
Bursi, R., Piana, C., Grevel, J., Huntjens, D., & Boesl, I. (2017) Evaluation of the Population Pharmacokinetic Properties of Lidocaine and its Metabolites After Long-Term Multiple Applications of a Lidocaine Plaster in Post-Herpetic Neuralgia Patients. Eur J Drug Metab Pharmacokinet.42(5):801–14.
Campbell, B. J., Rowbotham, M., Davies, P. S., Jacob, P., & Benowitz, N. L. (2002) Systemic absorption of topical lidocaine in normal volunteers, patients with post-herpetic neuralgia, and patients with acute herpes zoster. J Pharm Sci. 91(5):1343–50.
Casale, R., Di Matteo, M., Minella, C. E., Fanelli, G., & Allegri, M. (2014) Reduction of painful area as new possible therapeutic target in post-herpetic neuropathic pain treated with 5% lidocaine medicated plaster: A case series. Journal of Pain Research. 7, 353–7.
Clère, F., Delorme-Morin, C., George, B., Navez, M., Rioult, B., Tiberghien-Chatelain, F., et al. (2011) 5 Lidocaine medicated plaster in elderly patients with postherpetic neuralgia: Results of a compassionate use programme in france. Drugs and Aging. 28(9):693–702.
Dakin, H., Nuijten, M., Liedgens, H., Nautrup, B. P. (2007) Cost-Effectiveness of a Lidocaine 5% Medicated Plaster Relative to Gabapentin for Postherpetic Neuralgia in the United Kingdom. Clin Ther. 29(7):1491–507.
Fashner, J., & Bell, A. (2011) Herpes zoster and postherpetic neuralgia: prevention and management. Am Fam Physician. 2011;83(12):1432–7.
Galer, B. S., Rowbotham, M. C., Perander, J., & Friedman, E. (1999) Topical lidocaine patch relieves postherpetic neuralgia more effectively than a vehicle topical patch: Results of an enriched enrollment study. Pain. 80(3):533–8.
Goddard, J. M., & Reaney, R. L. (2018) Lidocaine 5%–medicated plaster (Versatis) for localised neuropathic pain: results of a multicentre evaluation of use in children and adolescents. Br J Pain. 12(3):189–93.
Gore, M., Sadosky, A., Tai, K. S., & Stacey, B. (2007) A Retrospective Evaluation of the Use of Gabapentin and Pregabalin in Patients with Postherpetic Neuralgia in Usual-Care Settings. Clin Ther. 29(8):1655–70.
Gudin, J., Fudin, J., Wang, E., Haylon, T., Patel, K., & Goss, T. F. (2019) Treatment patterns and medication use in patients with postherpetic neuralgia. J Manag Care Spec Pharm. 25(12):1387–96.
Hans, G., Sabatowski, R., Binder, A., Boesl, I., Rogers, P., & Baron, R. (2009) Efficacy and tolerability of a 5% lidocaine medicated plaster for the topical treatment of post-herpetic neuralgia: Results of a long-term study. In: Current Medical Research and Opinion. 1295–305.
Higgins, J. P. T., Altman, D. G., Gøtzsche, P. C., Jüni, P., Moher, D., Oxman, A. D., et al. (2011) The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ. 343(7829).
Katz, N. P., Gammaitoni, A. R., Davis, M. W., Dworkin, R. H., Avery, J., Burick, T., et al. (2002) Lidocaine patch 5% reduces pain intensity and interference with quality of life in patients with postherpetic neuralgia: An effectiveness trial. Pain Med. 3(4):324–32.
Kirson, N. Y., Ivanova, J. I., Birnbaum, H. G., Wei, R., Kantor, E., Amy Puenpatom, R., et al. (2010)a Descriptive analysis of Medicaid patients with postherpetic neuralgia treated with lidocaine patch 5%. J Med Econ. 13(3):472–81.
Kirson, N. Y., Ivanova, J. I., Birnbaum, H. G., Wei, R., Kantor, E., Puenpatom, R. A., et al. (2010)b Comparing healthcare costs of Medicaid patients with postherpetic neuralgia (PHN) treated with lidocaine patch 5% versus gabapentin or pregabalin. J Med Econ. 13(3):482–91.
Kontić, M., Vicic-Hudorović, V., & Hudorović, N. (2016) Treatment of postherpetic neuralgia with 5% topical lidocaine plaster - Experience from a small county hospital: Case report. Acta Clin Croat. 55(4):655–8.
Laurent, B., Vicaut, E., Leplège, A., Bloch, K., & Leutenegger, E. (2014) Prevalence and impact on quality of life of post-herpetic neuralgia in French medical centers specialized in chronic pain management: The ZOCAD study. Med Mal Infect.44(11–12):515–24.
Liedgens, H., Hertel, N., Gabriel, A., Nuijten, M., Dakin, H., Mitchell, S., et al. (2008) Cost-effectiveness analysis of a lidocaine 5% medicated plaster compared with gabapentin and pregabalin for treating postherpetic neuralgia: A German perspective. Vol. 28, Clinical Drug Investigation. 583–601.
Lin, P. L., Fan, S. Z., Huang, C. H., Huang, H. H., Tsai, M. C., Lin, C. J., et al. (2008) Analgesic Effect of Lidocaine Patch 5% in the Treatment of Acute Herpes Zoster: A Double-Blind and Vehicle-Controlled Study. Reg Anesth Pain Med. 33(4):320–5.
Lu, L, Suo, L, Li, J., & Pang, X. (2018) A retrospective survey on herpes zoster disease burden and characteristics in Beijing, China. Hum Vaccines Immunother. 2018;14(11):2632–5.
Malec-Milewska, M., Horosz, B., Sękowska, A., Kolęda, I., Kucia, H., & Kosson, D. (2015) 5% lidocaine medicated plasters vs. Sympathetic nerve blocks as a part of multimodal treatment strategy for the management of postherpetic neuralgia: A retrospective, consecutive, case-series study. Neurol Neurochir Pol. 49(1):24–8.
Metsker, O., Magoev, K., Yanishevskiy, S., Yakovlev, A., Kopanitsa, G., & Zvartau N. Identification of diabetes risk factors in chronic cardiovascular patients. In: Studies in Health Technology and Informatics. 136–41.
Nalamachu, S., Wieman, M., Bednarek, L., & Chitra, S. (2013) Influence of anatomic location of lidocaine patch 5% on effectiveness and tolerability for postherpetic neuralgia. Patient Prefer Adherence. 7:551–7.
Obradovic, M., Vanden, B. H., & Liedgens, H. (2014) Cost-Effectiveness of the Lidocaine 5% Medicated Plaster Verse Pregabalin and Amitriptyline for the Treatment of Post-Herpetic Neuralgia In the Netherlands. Value Heal. 17(7):A531.
Pedrosa, V. de C., A., Silva, J. G. A. (2013) Medicina baseada em evidências Avaliação do risco de viés de ensaios clínicos randomizados pela ferramenta da colaboração Cochrane. 18, Diagn Tratamento. 2013.
Pereira, M., Saúde TG-E e S de, U. (2014) Heterogeneidade e viés de publicação em revisões sistemáticas. SciELO Public Heal.
Pickering, G., Pereira, B., Clère, F., Sorel, M., de Montgazon, G., Navez, M., et al. (2014) Cognitive function in older patients with postherpetic neuralgia. Pain Pract 14(1). https://pubmed.ncbi.nlm.nih.gov/23701810/
Rehm, S., Binder, A., & Baron, R. (2010) Post-herpetic neuralgia: 5% lidocaine medicated plaster, pregabalin, or a combination of both A randomized, open, clinical effectiveness study. Curr Med Res Opin. 26(7):1607–19.
Ritchie, M., Liedgens, H., & Nuijten, M. (2010) Cost effectiveness of a lidocaine 5% medicated plaster compared with pregabalin for the treatment of postherpetic neuralgia in the UK: A Markov model Analysis. Clin Drug Investig. 30(2):71–87.
Rowbotham, M. C., Davies, P. S., Verkempinck, C., & Galer, B. S. (1996) Lidocaine patch: Double-blind controlled study of a new treatment method for post-herpetic neuralgia. Pain. 65(1):39–44.
Sabatowski, R., et al. Treatment of postherpetic neuralgia with 5% lidocaine medicated plaster in elderly patients–subgroup analyses from three European clinical trials. Curr Med Res Opin. 33(3):595–603.
Sabatowski R, et al.. (2012) Safety and efficacy outcomes of long-term treatment up to 4 years with 5 lidocaine medicated plaster in patients with post-herpetic neuralgia. Curr Med Res Opin. 28(8):1337–46.
Smith A, et al. (2021) Effect of an Online Reimbursement Application System on Prescribing of Lidocaine 5% Medicated Plaster in the Republic of Ireland. Appl Health Econ Health Policy.19(1):133–40.
Wang, Y. F., et al. (2020) Persistence of pregabalin treatment in Taiwan: A nation-wide population-based study. J Headache Pain. 21(1).
Wasner, G, et al. (2005) Postherpetic neuralgia: Topical lidocaine is effective in nociceptor-deprived skin. J Neurol. 252(6):677–86.
Wehrfritz, A., et al. (2011) Differential effects on sensory functions and measures of epidermal nerve fiber density after application of a lidocaine patch (5%) on healthy human skin. Eur J Pain. 15(9):907–12.
Descargas
Publicado
Cómo citar
Número
Sección
Licencia
Derechos de autor 2021 Ricardo Grillo; Marília Coelho Oliveira Dutra Leal; Antônio Augusto Campanha; Claudio Roberto Pacheco Jodas; Rubens Gonçalves Teixeira
Esta obra está bajo una licencia internacional Creative Commons Atribución 4.0.
Los autores que publican en esta revista concuerdan con los siguientes términos:
1) Los autores mantienen los derechos de autor y conceden a la revista el derecho de primera publicación, con el trabajo simultáneamente licenciado bajo la Licencia Creative Commons Attribution que permite el compartir el trabajo con reconocimiento de la autoría y publicación inicial en esta revista.
2) Los autores tienen autorización para asumir contratos adicionales por separado, para distribución no exclusiva de la versión del trabajo publicada en esta revista (por ejemplo, publicar en repositorio institucional o como capítulo de libro), con reconocimiento de autoría y publicación inicial en esta revista.
3) Los autores tienen permiso y son estimulados a publicar y distribuir su trabajo en línea (por ejemplo, en repositorios institucionales o en su página personal) a cualquier punto antes o durante el proceso editorial, ya que esto puede generar cambios productivos, así como aumentar el impacto y la cita del trabajo publicado.
